| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the molecular and cellular mechanisms of chronic GVHD-associated impairments in bone marrow (BM) mesenchymal cells to establish the bases for novel prevention and therapy for allo-HSCT. In a murine chronic GVHD model, we found the development of broad suppression of hematopoiesis and BM fibrosis. PDGF and CTGF signaling are involved in the activation of Nf-kb and Stat pathway, and inhibition of PDGF signaling suppressed the BM fibrosis. Early administration of anti-CD4 mAb prevented BM failure. These findings may provide a preventive and therapeutic clue to improve the survival and QOL after allo-HSCT.
|
